| Neurocan is upregulated in injured brain and in cytokine-treated astrocytes RA Asher, DA Morgenstern, PS Fidler, KH Adcock, A Oohira, JE Braistead, ... Journal of Neuroscience 20 (7), 2427-2438, 2000 | 620 | 2000 |
| Chondroitin sulphate proteoglycans in the CNS injury response DA Morgenstern, RA Asher, JW Fawcett Progress in brain research 137, 313-332, 2002 | 600 | 2002 |
| Versican is upregulated in CNS injury and is a product of oligodendrocyte lineage cells RA Asher, DA Morgenstern, MC Shearer, KH Adcock, P Pesheva, ... Journal of Neuroscience 22 (6), 2225-2236, 2002 | 314 | 2002 |
| Matrix metalloproteases and their inhibitors are produced by overlapping populations of activated astrocytes EM Muir, KH Adcock, DA Morgenstern, R Clayton, N Von Stillfried, ... Molecular Brain Research 100 (1-2), 103-117, 2002 | 252 | 2002 |
| Chondroitin sulphate proteoglycans: inhibitory components of the glial scar RA Asher, DA Morgenstern, LDF Moon, JW Fawcett Progress in brain research 132, 611-619, 2001 | 231 | 2001 |
| Human γδ T lymphocytes are licensed for professional antigen presentation by interaction with opsonized target cells N Himoudi, DA Morgenstern, M Yan, B Vernay, L Saraiva, Y Wu, ... The Journal of Immunology 188 (4), 1708-1716, 2012 | 165 | 2012 |
| Current and future strategies for relapsed neuroblastoma: challenges on the road to precision therapy DA Morgenstern, S Baruchel, MS Irwin Journal of pediatric hematology/oncology 35 (5), 337-347, 2013 | 106 | 2013 |
| Surround repulsion of spinal sensory axons in higher vertebrate embryos R Keynes, D Tannahill, DA Morgenstern, AR Johnson, GMW Cook, A Pini Neuron 18 (6), 889-897, 1997 | 93 | 1997 |
| Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiency A Das, S Sudhaman, D Morgenstern, A Coblentz, J Chung, SC Stone, ... Nature medicine 28 (1), 125-135, 2022 | 91 | 2022 |
| Anti-tumor activity of the beta-adrenergic receptor antagonist propranolol in neuroblastoma JK Wolter, NE Wolter, A Blanch, T Partridge, L Cheng, DA Morgenstern, ... Oncotarget 5 (1), 161, 2014 | 90 | 2014 |
| Expression and glycanation of the NG2 proteoglycan in developing, adult, and damaged peripheral nerve DA Morgenstern, RA Asher, M Naidu, T Carlstedt, JM Levine, JW Fawcett Molecular and Cellular Neuroscience 24 (3), 787-802, 2003 | 87 | 2003 |
| Polyphenol E enhances the antitumor immune response in neuroblastoma by inactivating myeloid suppressor cells G Santilli, I Piotrowska, S Cantilena, O Chayka, M D'Alicarnasso, ... Clinical cancer research 19 (5), 1116-1125, 2013 | 85 | 2013 |
| Two separate metalloproteinase activities are responsible for the shedding and processing of the NG2 proteoglycan in vitro RA Asher, DA Morgenstern, F Properzi, A Nishiyama, JM Levine, ... Molecular and Cellular Neuroscience 29 (1), 82-96, 2005 | 84 | 2005 |
| Prognostic significance of pattern and burden of metastatic disease in patients with stage 4 neuroblastoma: A study from the International Neuroblastoma Risk Group database DA Morgenstern, WB London, D Stephens, SL Volchenboum, T Simon, ... European Journal of Cancer 65, 1-10, 2016 | 82 | 2016 |
| Clinical and pathological features of paediatric malignant rhabdoid tumours DA Morgenstern, S Gibson, T Brown, NJ Sebire, J Anderson Pediatric blood & cancer 54 (1), 29-34, 2010 | 82 | 2010 |
| Risk stratification of high‐risk metastatic neuroblastoma: a report from the HR‐NBL‐1/SIOPEN study DA Morgenstern, U Pötschger, L Moreno, V Papadakis, C Owens, S Ash, ... Pediatric blood & cancer 65 (11), e27363, 2018 | 70 | 2018 |
| DNA polymerase and mismatch repair exert distinct microsatellite instability signatures in normal and malignant human cells J Chung, YE Maruvka, S Sudhaman, J Kelly, NJ Haradhvala, V Bianchi, ... Cancer discovery 11 (5), 1176-1191, 2021 | 66 | 2021 |
| Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results KC Goldsmith, JR Park, K Kayser, J Malvar, YY Chi, SG Groshen, ... Nature medicine 29 (5), 1092-1102, 2023 | 65 | 2023 |
| The challenge of defining “ultra‐high‐risk” neuroblastoma DA Morgenstern, R Bagatell, SL Cohn, MD Hogarty, JM Maris, L Moreno, ... Pediatric Blood & Cancer 66 (4), e27556, 2019 | 63 | 2019 |
| Accelerating drug development in pediatric cancer: a novel Phase I study design of venetoclax in relapsed/refractory malignancies AE Place, K Goldsmith, JP Bourquin, ML Loh, L Gore, DA Morgenstern, ... Future Oncology 14 (21), 2115-2129, 2018 | 63 | 2018 |
Meredith IrwinHospital for Sick Children; Professor, University of Toronto在 sickkids.ca 的电子邮件经过验证
